Abcam, ab317270, Anti-Total OXPHOS Antibody Cocktail antibody [RM1134]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Multiclonal NDUFB8 antibody. Suitable for ICC/IF, Flow Cyt (Intra), WB, IHC-P and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Multiclonal,
Clone number:RM1134,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:Flow Cyt (Intra), IHC-P, WB, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:This product was produced with the following immunogens:The exact immunogen used to generate this antibody is proprietary information.The exact immunogen used to generate this antibody is proprietary information.The exact immunogen used to generate this antibody is proprietary information.The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody cocktail does cross-react with NDUFB8, SDHB, UQCRC2 and ATP5A from mouse and rat samples.

Product details:
What are recombinant multiclonals?
Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including:
- The sensitivity of polyclonal antibodies by recognising multiple epitopes
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
View our range of
recombinant multiclonal antibodies
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Total OXPHOS Antibody Cocktail targets key proteins involved in oxidative phosphorylation (OXPHOS) a critical process for ATP production in mitochondria. It includes antibodies against five complexes of the electron transport chain often known as complexes I-V. These complexes are expressed in mitochondria within almost all eukaryotic cells especially high-energy demanding tissues like muscle and brain. The molecular weight of these complex components varies but each plays an important role in transferring electrons during ATP synthesis.
Biological function summary
These complexes form the core of the electron transport chain an assembly of protein complexes embedded in the mitochondrial inner membrane. OXPHOS as part of this chain is important for cellular respiration and metabolic energy production. Proteins within these complexes work together to generate a proton gradient that drives ATP synthase activity. The efficient function of this system supports high demands of cellular energy and is essential for maintaining metabolic homeostasis.
Pathways
The Total OXPHOS Antibody Cocktail components integrate into the oxidative phosphorylation and citric acid cycle pathways. Energy transduction from NADH and FADH2 through the electron transport chain connects OXPHOS with these pathways. Cytochrome c an important protein acts as an electron shuttle between complex III and complex IV within this process highlighting its importance for proper function and energy production.
Irregularities in OXPHOS function link to disorders such as mitochondrial myopathy and Leber's hereditary optic neuropathy. These conditions often result from mutations impacting the electron transport chain proteins disrupting ATP production and leading to energy deficits in cells. For instance mutations in NADH:ubiquinone oxidoreductase (complex I) contribute to disease development emphasizing the need for understanding these targets to develop potential therapeutic strategies.